Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology
Scientific Editors:George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)
Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology Annual Meeting, May 30-June 3, 2008, Chicago
Michael Gnant
In this edition:
1. Zoledronic Acid Reduces Recurrence In Early-Stage Breast Cancer
Michael Gnant, Medical University of Vienna, AustriaABSTRACT: LBA4
2. Bevacizumab Slows Progression In Advanced Breast Cancer
David Miles, Mount Vernon Cancer Centre, LondonABSTRACT: LBA 1011
3. Discussion: Zoledronic Acid; Bevacizumab in Breast Cancer
Eric Winer, Dana-Farber Cancer Institute, BostonABSTRACT: LBA 4 & LBA 1011
4. Oral Capecitabine: Not For Older Patients with Early Breast Cancer
Hyman Muss, University of Vermont, BurlingtonABSTRACT: 507
5. Endometrial Cancer: Brachytherapy Is Better
Remi Nout, Leiden University Medical CenterABSTRACT: LBA 5503
6. Adjuvant Gemcitabine Doubles Survival In Resected Pancreas Cancer
Helmut Oettle, Charité University, BerlinABSTRACT: LBA 4504
7. Everolimus Delays Metastatic Kidney Cancer Progression
Robert Motzer, Memorial Sloan-Kettering Cancer Center, New YorkABSTRACT: LBA 5026
8. Discussion: Gemcitabine For Pancreas Cancer; Brachytherapy for Endometrial Cancer
Nicholas Petrelli, Helen F Graham Cancer Center, WilmingtonABSTRACTS: LBA 5503; LBA 4504; LBA5026
Buy Audio Journal of Oncology Digital CopyOrder Audio Journal of Oncology CDLISTEN
Tags
Related Episodes
Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”
Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer
Eileen M O'Reilly MD; ASCO 2026: RAS G12 Targeting Drug Daraxonrasib Doubles Survival with Pancreas Cancer in Phase 3 RASolute 302 Study
Standing ovation at ASCO for RASolute 302 Study
Aditya Bardia MD MPH; 2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings
A seective estrogen degrader out-performed AI’s in ER+ HER- early breast cancer